Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity

Brar, Simrandeep K; Perveen, Sumera; Chaudhry, Muhammad Reza; Albabtain, Sarah; Amreen, Sana; Khan, Safeera

doi:10.7759/cureus.12804

Cited by 12 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher dosages or prolonged usage of EPO are more likely to cause this side effect. Careful monitoring of blood pressure and titration of EPO dose as appropriate allows for effective management of hypertension 72 . Furthermore, thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism, have been linked to EPO medication.…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin mitigated thioacetamide-induced renal injury via JAK2/STAT5 and AMPK pathway

Elbaset,

Mohamed,

Gad

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The kidney flushes out toxic substances and metabolic waste products, and homeostasis is maintained owing to the kidney efforts. Unfortunately, kidney disease is one of the illnesses with a poor prognosis and a high death rate. The current investigation was set out to assess erythropoietin (EPO) potential therapeutic benefits against thioacetamide (TAA)-induced kidney injury in rats. EPO treatment improved kidney functions, ameliorated serum urea, creatinine, and malondialdehyde, increased renal levels of reduced glutathione, and slowed the rise of JAK2, STAT5, AMPK, and their phosphorylated forms induced by TAA. EPO treatment also greatly suppressed JAK2, Phosphatidylinositol 3-kinases, and The Protein Kinase R-like ER Kinase gene expressions and mitigated the histopathological alterations brought on by TAA toxicity. EPO antioxidant and anti-inflammatory properties protected TAA-damaged kidneys. EPO regulates AMPK, JAK2/STAT5, and pro-inflammatory mediator synthesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Erythropoietin mitigated thioacetamide-induced renal injury via JAK2/STAT5 and AMPK pathway

Elbaset,

Mohamed,

Gad

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Based on a meta-analysis of 52 clinical trials, using erythropoietin-stimulating agents to treat cancer-related anemia causes hypertension and increases adverse events such as mortality [ 83 ]. Vasoconstriction of vessels by rising levels of ET-1 and constrictor prostanoids, calcium influx in smooth muscle cells of blood vessels, and anti-natriuresis are underlying mechanisms of erythropoietin-stimulating agents-induced hypertension [ 84 ].…”

Section: Etiologies Of Cancer Treatment-induced Hypertensionmentioning

confidence: 99%

Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management

Askarinejad,

Alizadehasl,

Jolfayi

et al. 2023

Cardio-Oncology

View full text Add to dashboard Cite

Hypertension is one of the most common comorbidity and the leading cause of cancer-related death in cancer patients. The prevalence of hypertension in cancer patients is much higher than that of the general population. In the older population of cancer patients, specific cancer treatments such as new tyrosine kinase inhibitors and Vascular endothelial growth factor inhibitor drugs give rise to hypertension in cancer patients; The aim of present study is to provide a detailed discussion etiologies of cancer treatment-induced hypertension and explore the most innovative diagnostic and management approaches. This review will address the optimal approach to hypertension treatment, covering treatment initiation thresholds, targets, and the selection of anti-hypertensive agents. The lack of evidence in recent guidelines for managing cardiovascular toxicities in cancer patients can create uncertainty in clinicians' therapeutic and clinical decisions. This review aims to enhance our understanding of hypertension etiology in cancer patients and provide a practical guide to current treatment approaches.

show abstract

“…An important subgroup of patients includes those with chronic kidney disease or preexisting arterial hypertension. For these individuals, the introduction of ESAs should be cautious, and a gradual correction of anemia is advised [54].…”

Section: Foliate and Vitamin B 12 Deficiencymentioning

confidence: 99%

Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm

Tałasiewicz,

Kapała

2023

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Cancer-related anemia (CRA) continues to be a critical concern despite advancements in oncology treatments. The prevalence of anemia varies from 30% to 90%, impacting the quality of life and prognosis of cancer patients. While CRA is often attributed to antineoplastic therapies, it can also result from the disease itself. Inflammation and the iron regulatory hormone hepcidin play significant roles in CRA pathogenesis. Treatment-induced anemia caused by chemotherapy, tyrosine kinase inhibitors (TKIs) and immunotherapy, pose additional challenges. Intravenous (IV) iron has emerged as an effective treatment option for CRA, overcoming limitations associated with oral iron supplementation. Combining IV iron and ESAs enhances treatment outcomes. Future directions involve exploring ESA safety and their immunomodulatory effects. Transfusions provide quick relief but might impact prognosis and immune response. Other considerations include incorporating physical activity and exploring hepcidin-directed therapy. In conclusion, CRA management necessitates a multifaceted approach to address deficiencies, optimize therapies and improve patient outcomes.

show abstract

Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity

Cited by 12 publications

References 25 publications

Erythropoietin mitigated thioacetamide-induced renal injury via JAK2/STAT5 and AMPK pathway

Erythropoietin mitigated thioacetamide-induced renal injury via JAK2/STAT5 and AMPK pathway

Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management

Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm

Contact Info

Product

Resources

About